Financial Performance - The net profit attributable to shareholders for 2024 is projected to be between ¥22 million and ¥25 million, representing an increase of 31.97% to 49.97% compared to the previous year's ¥16.67 million[3]. - The net profit after deducting non-recurring gains and losses is expected to be between ¥20 million and ¥22.5 million, reflecting a growth of 45.18% to 63.33% from last year's ¥13.78 million[3]. Product Development - The company has made significant progress in developing new products, particularly the Zhi Shi series, which has contributed to the revenue growth in the domestic market[4]. - The company has expanded its product applications into the food additive sector, attracting new clients and further boosting net profit[4]. Caution for Investors - The financial data presented is preliminary and has not been audited, emphasizing the need for investors to exercise caution[5].
欧康医药(833230) - 2024 Q4 - 年度业绩预告